varieti
infect
transmit
donor
recipi
kidney
transplant
outcom
rang
mildli
troublesom
fatal
avoid
unpleas
transplant
programm
institut
varieti
screen
procedur
see
tabl
screen
watertight
therefor
care
clinic
assess
critic
interpret
risk
key
recipi
serolog
also
crucial
assess
risk
serum
accompani
donor
organ
thu
test
receiv
unit
serolog
felt
relev
infecti
agent
tend
hierarchi
virul
posttranspl
primari
infect
wors
reinfect
virul
reactiv
risk
stratif
therefor
highli
import
identif
erad
control
infect
well
vaccin
prelist
appropri
prophylaxi
posttranspl
alway
done
well
might
tabl
show
infect
treat
control
pretranspl
vaccin
either
recommend
consid
ground
common
sens
addit
nonspecif
clinic
featur
unexplain
splenomegali
lymphadenopathi
persist
rais
crp
eosinophilia
polyclon
gammopathi
absenc
autoimmun
need
explain
list
patient
previous
receiv
high
dose
immunosuppress
chemotherapi
recurr
viral
eg
herp
bacteri
infect
import
check
immunoglobulin
level
lymphocyt
subset
worth
note
immunosuppress
posttranspl
reduc
seroconvers
rate
around
achiev
control
patient
evid
suggest
second
dose
vaccin
offer
benefit
nonetheless
clear
vaccin
benefit
save
live
built
transplant
programm
whenev
possibl
vaccin
undertaken
predialysi
particular
live
attenu
vaccin
must
given
immunosuppress
given
posttranspl
sever
set
guidelin
recommend
posttranspl
prophylaxi
tabl
illustr
main
recommend
pretranspl
vaccin
unit
frequent
inconsist
area
posttranspl
prophylaxi
tb
prevent
cultur
perfus
hepat
b
followup
robust
system
ensur
patient
appropri
consid
posttranspl
prophylaxi
line
local
polici
critic
ensur
patient
safeti
although
absolut
clinic
help
timelin
infect
posttranspl
expound
rubin
week
infect
mostli
direct
result
surgeri
ie
chest
wound
infect
lineassoci
sepsi
occasion
bacteri
infect
deriv
donor
posit
perfus
cultur
donor
uti
donor
bacteraemia
unexplain
meningoencephalit
ill
week
predominantli
nosocomi
infect
relat
stay
hospitalis
ie
uti
line
pd
catheterassoci
infect
clostridium
difficil
oral
oesophag
candidiasi
also
common
stage
especi
patient
steroid
herp
virus
primari
hsv
unusu
present
earli
stage
virus
transmit
wnv
also
present
week
period
domin
opportunist
infect
relat
heaviest
period
immunosuppress
herp
virus
reactiv
primari
infect
eg
cmv
absenc
prophylaxi
typic
day
ebv
hsv
vzv
shingl
respiratori
virus
may
present
chest
involv
invas
fungal
infect
candida
aspergillu
tend
present
period
may
mycobacterium
tb
parasit
infect
reactiv
strongyloid
toxoplasmosi
tend
occur
earli
uti
remain
common
absenc
prophylaxi
pcp
present
period
week
period
viral
reactiv
hsv
vzv
shingl
occur
stage
small
proport
patient
develop
high
level
ebv
viraemia
often
mani
year
posttranspl
viral
wart
also
common
first
year
lateonset
cmv
present
usual
within
week
follow
cessat
prophylaxi
orogenit
hsv
may
also
recur
incident
infect
listeria
legionella
respiratori
viral
infect
occur
time
cmv
ebv
vzv
hsvneg
patient
acquir
primari
infect
mani
year
posttranspl
particularli
young
famili
becom
expos
young
children
mtb
tend
present
rel
earli
cours
transplant
nontubercul
mycobacteria
ntm
tend
present
later
cryptococcu
tend
present
late
pcp
occur
stage
although
risk
diminish
time
nb
hepat
b
c
reactiv
occur
time
especi
cessat
prophylaxi
hepat
b
promot
use
steroid
uti
posttranspl
common
associ
signific
morbid
hospitalis
graft
loss
definit
constitut
complic
uti
uti
posttranspl
cover
detail
worth
emphasis
patient
abnorm
anatomi
recurr
uti
pretranspl
like
signific
problem
urosepsi
posttranspl
unless
underli
caus
resolv
b
transplant
uti
definit
complic
short
cours
antibiot
may
result
partial
treat
recurr
infect
high
risk
gener
multipl
admiss
highli
resist
organ
c
patient
recurr
sever
urosepsi
need
prompt
assess
uroloradio
nephrolog
mdt
cmv
beta
herp
viru
common
opportunist
infect
posttranspl
renal
transplant
develop
viraemia
repres
signific
challeng
organ
transplant
recipi
cmv
seropreval
higher
rate
africa
lower
rate
northern
europ
usa
increas
preval
age
transmiss
via
saliva
urin
sexual
contact
breastfeed
placent
transmiss
blood
transfus
transplant
immunocompet
host
primari
infect
usual
asymptomat
although
present
mononucleosislik
ill
follow
viru
undergo
prolong
period
latenc
becom
reactiv
varieti
mechan
includ
stress
sepsi
immunosuppress
exampl
tnfalpha
releas
reject
infect
activ
major
immedi
earli
promot
miep
cmv
induc
intracellular
replic
transplant
recipi
occasion
worth
rememb
patient
immunosuppress
autoimmun
condit
primari
infect
reinfect
differ
strain
dr
reactiv
risk
viraemia
strongli
associ
statu
addit
use
deplet
antibodi
induct
acut
reject
poor
graft
function
older
donor
age
known
risk
factor
renal
transplant
predominantli
induc
mab
prophylaxi
viraemia
occur
dr
none
peak
viral
load
also
significantli
higher
patient
clinic
characterist
mani
patient
viraemia
asymptomat
strong
correl
viral
load
symptom
clinic
characterist
cmv
infect
immunocompromis
shown
tabl
viraemia
clinic
featur
usual
occur
week
typic
posttranspl
easi
caught
diseas
occur
outsid
period
follow
treatment
late
reject
b
cessat
prophylaxi
c
transplant
follow
primari
exposur
sometim
year
later
kinet
viral
replic
clinic
relev
primari
infect
associ
doubl
time
day
vs
day
reactiv
mean
cmv
patient
go
asymptomat
low
detect
viral
load
signific
endorgan
diseas
within
week
patient
primari
infect
often
present
socal
cmv
syndrom
high
fever
without
localis
physic
sign
progress
rapidli
gastriti
coliti
often
bloodi
pneumon
endorgan
involv
usual
associ
high
viral
load
patient
reactiv
reinfect
may
less
fulmin
cours
isol
coliti
pneumon
without
obviou
fullblown
viral
syndrom
either
way
endorgan
damag
progress
rapidli
occur
lowlevel
viraemia
rare
absenc
viraemia
therefor
high
index
suspicion
requir
cmv
immunosuppress
right
often
open
door
opportunist
infect
ebv
pcp
clinic
characterist
cmv
infect
tabl
diagnosi
cmv
infect
base
detect
viru
either
antigenaemia
detect
quantif
cmv
nucleic
acid
test
realtim
quantit
pcr
practic
laboratori
use
realtim
pcr
adher
univers
diagnost
standard
techniqu
highli
reproduc
concern
pcr
would
result
fals
posit
experi
although
viraemia
common
modern
manag
clinic
diseas
affect
renal
transplant
recipi
vast
major
cmv
syndrom
howev
endorgan
diseas
occur
devast
rapidli
progress
pneumon
may
present
short
breath
oxygen
desatur
postexercis
may
progress
swiftli
mild
dyspnoea
mark
desatur
particularli
mild
exert
chest
xray
see
fig
ct
scan
may
show
sign
interstiti
lung
diseas
wide
differenti
essenti
get
sampl
rapidli
ideal
bronchoalveolar
lavag
possibl
treat
blindli
cover
cmv
import
note
cmv
infect
predispos
infect
viral
pneumon
coexist
pneumocysti
pneumon
mening
enceph
may
present
classic
symptom
sign
epilepsi
impair
cognit
diagnos
pcr
csf
ensur
appropri
sampl
taken
time
lumbar
punctur
import
possibl
tissueinvas
diseas
gastriti
coliti
fig
nephriti
fig
biopsi
cultur
pcr
critic
howev
pancrea
retina
lessapp
biopsi
target
ophthalmologist
normal
make
firm
clinic
diagnosi
cmv
pancreat
usual
therefor
presumpt
diagnosi
base
viraemia
clinic
find
short
import
high
index
suspicion
transplant
endorgan
diseas
rapid
request
process
blood
tissu
cmv
pcr
possibleappropri
ensur
biopsi
sent
virolog
well
histopatholog
depart
beyond
direct
effect
viru
cmv
infect
implic
sever
indirect
consequ
includ
increas
cellular
reject
b
increas
infect
microb
c
increas
mortal
wors
graft
surviv
without
controversi
instanc
studi
show
associ
acut
cellular
reject
alway
differenti
caus
effect
signific
proport
experi
acut
reject
preced
cmv
viraemia
much
associ
may
simpli
respons
increas
immunosuppress
cmv
viraemia
immunomodulatori
predispos
ebv
viraemia
well
increas
fungal
infect
although
cmv
viraemia
may
also
biomark
immunosuppress
studi
shown
increas
mortal
wors
graft
surviv
also
shown
howev
uk
studi
base
serolog
transplant
show
effect
patient
allograft
surviv
detail
analysi
beyond
scope
chapter
clear
overt
cmv
diseas
nasti
best
avoid
varieti
recommend
prevent
treatment
cmv
posttranspl
bt
guidelin
nice
summaris
current
evid
kidney
transplant
guidelin
favour
univers
prophylaxi
posit
recipi
especi
follow
deplet
antibodi
part
base
metaanalys
prophylaxi
studi
demonstr
benefit
caus
mortal
prophylaxi
studi
metaanalys
short
followup
patient
preemptiv
arm
guidelin
mostli
acknowledg
preemptiv
therapi
probabl
equal
appropri
logist
robustli
manag
case
preemptiv
prophylaxi
eloqu
argu
thoma
reischig
suggest
prevail
opinion
move
toward
equal
recommend
preemptiv
prophylaxi
main
advantag
univers
prophylaxi
includ
eas
administr
coprophylaxi
virus
primari
hsv
disadvantag
includ
drug
side
effect
especi
leucopenia
concern
lateonset
diseas
advantag
preemptiv
approach
includ
limit
drug
exposur
need
encourag
immun
near
complet
absenc
late
diseas
disadvantag
preemptiv
therapi
includ
extra
vigil
requir
lack
coprophylaxi
summaris
current
guidelin
prevent
recommend
prophylaxi
valgancyclovir
superior
acyclovir
valacyclovir
oral
gancyclovir
start
within
day
transplant
r
patient
base
find
impact
studi
show
reduc
rate
lateonset
cmv
diseas
compar
day
treatment
vs
guidelin
tend
favour
treatment
day
receiv
deplet
antibodi
atg
dose
recommend
normal
renal
function
mg
per
day
mg
appear
effect
caus
much
less
leucopenia
potenti
increas
risk
resist
dose
reduct
renal
impair
requir
risk
cmv
diseas
low
requir
cmv
prophylaxi
therefor
mandat
antihsv
prophylaxi
clinician
need
vigil
cmv
postprophylaxi
system
monitor
patient
time
well
alert
possibl
viral
resist
noncompli
prophylaxi
experi
preemptiv
approach
posit
cmv
syndrom
develop
endorgan
diseas
approxim
lateonset
viraemia
first
episod
day
import
caution
includ
tabl
preemptiv
therapi
reli
robust
monitor
report
well
good
relationship
virolog
depart
rapid
doubl
time
primari
infect
ensur
twice
weekli
cmv
monitor
first
week
longer
episod
viraemia
weekli
week
email
report
servic
transplant
team
clear
line
respons
work
well
give
patient
day
valgancyclovir
discharg
start
viraemia
detect
outpati
patient
admit
hospit
team
may
risk
monitor
report
breakdown
import
strategi
patient
final
clear
patient
viraemia
deplet
antibodi
high
immunolog
risk
ie
earli
reject
therefor
risk
immunosuppress
reduct
isr
highli
like
recurr
viraemia
complet
treatment
may
worth
consid
convert
prophylaxi
treatment
advantag
recipi
develop
immun
first
viraemia
treatment
asymptomat
serolog
posit
r
patient
viral
count
genomesml
practic
reduc
overal
burden
immunosuppress
cni
level
high
antiprolif
treat
reactiv
viraemia
genomesml
evid
endorgan
diseas
unit
practis
preemptiv
therapi
cmv
patient
posit
donor
discharg
day
valgancyclovir
starter
pack
take
singl
posit
pcr
level
avoid
delay
treatment
also
worth
consid
postprophylaxi
firstlin
treatment
signific
viraemia
cmv
diseas
valgancyclovir
iv
gancyclovir
especi
latter
doubt
absorpt
dose
adjust
egfr
see
tabl
patient
recent
undergon
reject
advis
reduc
antiprolif
agent
consid
stop
altogeth
seriou
diseas
treatment
cmv
diseas
continu
least
week
even
earli
elimin
viraemia
practic
continu
treatment
two
neg
pcr
everyon
relaps
common
especi
receiv
deplet
antibodi
insuffici
evid
support
use
ivig
cmv
ab
enrich
otherwis
expens
scarc
resourc
like
rel
harmless
might
worth
consid
tight
corner
patient
respond
antivir
import
ensur
pcp
prophylaxi
continu
gcsf
help
face
neutropenia
viral
resist
much
common
subgroup
prolong
treatment
use
deplet
antibodi
apart
highrisk
group
strong
indic
resist
failur
clear
viru
week
mutat
analysi
request
set
mutat
kinas
dna
polymeras
current
recognis
marker
resist
import
note
gancyclovir
cidofovir
foscarnet
target
dna
polymeras
resist
gancyclovir
lead
cross
resist
cidofovir
foscarnet
latter
two
drug
reserv
secondlin
drug
gener
revil
nephrologist
high
rate
nephrotox
nonetheless
lifesav
extrem
diseas
dose
need
care
adjust
gfr
prehydr
essenti
leflunomid
mtor
inhibitor
theoret
anticmv
properti
case
report
success
use
leflunomid
treat
resist
cmv
sot
howev
like
report
bia
yet
rct
support
use
leflunomid
treatment
circumstanti
evid
favour
clinic
relev
anticmv
effect
mtor
inhibitor
convinc
mani
studi
show
significantli
reduc
rate
cmv
infect
de
novo
kidney
transplant
receiv
mtor
inhibitor
evid
mtor
inhibitor
help
treatment
cmv
infect
degener
anecdot
small
case
seri
experi
nich
may
prove
import
patient
persist
resist
cmv
toler
reduct
immunosuppress
swap
tacrolimu
sirolimu
ad
sirolimu
tacrolimu
high
immunolog
risk
patient
dose
reduct
cni
effect
clear
cmv
simultan
avoid
reject
modern
manag
cmv
diseas
major
cmv
syndrom
affect
renal
transplant
experi
preemptiv
approach
treatment
requir
dr
viraemia
endorgan
diseas
occur
reactiv
hsv
form
nasolabi
cold
sore
genit
ulcer
rel
common
aggress
significantli
immunocompromis
see
fig
patient
may
give
histori
previou
cold
sore
frequent
pretranspl
highli
like
recur
posttranspl
prevent
readi
access
topic
acyclovir
lowdos
oral
acyclovir
prophylaxi
eg
mg
daili
treatment
oral
acyclovir
valacyclovir
famcyclovir
highli
effect
start
earli
dose
adjust
gfr
import
hsv
also
affect
cornea
conjunctiva
present
red
eyekerat
progress
dendrit
ulcer
potenti
sight
loss
fig
pain
red
eye
viral
swab
rapid
ophthalmolog
review
rare
seroneg
patient
develop
fulmin
primari
hsv
infect
report
high
mortal
high
fever
univers
skin
lesion
present
half
patient
may
explain
delay
diagnosi
patient
may
seem
better
fever
would
impli
initi
without
treatment
pancytopenia
gastric
ulcer
acut
hepat
ct
imag
may
appear
abscess
rapidli
progress
encephalopathi
coagulopathi
death
diagnosi
made
detect
hsv
dna
blood
csf
swab
biopsi
howev
onset
death
short
high
index
suspicion
import
earli
empir
treatment
critic
cmv
prophylaxi
valgancyclovir
essenti
protect
primari
hsv
hsvneg
patient
cmv
prophylaxi
given
either
acyclovir
valacyclovir
regardless
donor
statu
consensu
durat
prophylaxi
practic
give
valacyclovir
mg
bid
first
month
transplant
hsv
sensit
acyclovir
mention
suspicion
fulmin
hsv
prompt
rapid
iv
treatment
mgkg
tid
reduct
antiprolif
placement
high
depend
unit
reactiv
herp
zoster
shingl
markedli
common
transplant
recipi
gener
popul
occur
roughli
patient
first
year
fig
commonli
still
receiv
lymphocytedeplet
antibodi
neuralgia
preced
rash
diagnosi
initi
miss
consid
anyon
new
onset
sever
otherwis
unexplain
pain
treatment
acyclovir
valacyclovir
day
analgesia
surveil
secondari
infect
usual
reduct
antiprolif
primari
infect
potenti
lifethreaten
solidorgan
transplant
recipi
adult
popul
vzv
other
bear
similar
risk
hypogammoglobulinaem
identif
patient
wait
list
mandatori
vaccin
robustli
embed
pretranspl
programm
although
evid
commun
poor
vaccin
usual
given
two
dose
week
apart
live
vaccin
offer
acyclovir
patient
receiv
transplant
within
week
vaccin
patient
unlucki
enough
get
primari
varicella
infect
influenc
signific
immunosuppress
present
pneumon
hepat
ulcer
gastriti
coliti
pancreat
enceph
mening
dic
follow
swiftli
mortal
treatment
primari
chickenpox
rapid
initi
iv
acyclovir
mgkg
tid
adjust
gfr
day
usual
lesion
crust
treatment
may
need
continu
longer
week
cn
involv
dissemin
infect
cours
desir
avoid
risk
primari
infect
seroneg
patient
identifi
pretranspl
advis
avoid
exposur
given
clear
written
advic
expos
either
chickenpox
shingl
often
unwittingli
transplant
clinic
wait
room
pretranspl
serostatu
known
urgent
vzv
igg
test
requir
establish
vzv
immun
statu
attend
hospit
within
h
day
exposur
varicella
zoster
immun
globulin
vzig
mg
im
adult
dose
second
exposur
occur
week
dose
may
requiredif
vzig
unavail
expos
patient
given
im
inject
contraind
bleed
disord
ivig
use
g
per
kg
bodi
weight
consid
acyclovirvalacyclovir
famcyclovir
prophylaxi
household
contact
ebv
gammaherp
viru
world
seropreval
mostli
acquir
asymptomat
childhood
infecti
mononucleosi
im
puberti
immortalis
bcell
line
remain
mostli
latent
occasion
lytic
cycl
shed
mostli
saliva
healthi
individu
given
preval
ebv
infect
primari
infect
follow
transplant
common
seroneg
recipi
viraemia
common
posttranspl
occur
roughli
patient
usual
asymptomat
occasion
patient
may
present
im
nonspecif
viral
ill
greatest
concern
propens
ebv
induc
posttranspl
lymphoprolif
disord
ptld
nineti
percent
earli
ptld
ebv
posit
primari
infect
posttranspl
confer
risk
ptld
greater
still
concomit
cmv
infect
andor
use
deplet
antibodi
also
data
support
ebv
viraemia
preced
develop
ptld
howev
recent
guidelin
make
reason
point
evid
support
routin
monitor
ebv
level
postren
transplant
renal
associ
guidelin
howev
recommend
ebv
pcr
monitor
dr
patient
first
year
follow
treatment
reject
despit
lack
evid
risk
stratif
key
worth
consid
monitor
patient
especi
receiv
deplet
antibodi
patient
viraem
pretranspl
usual
previou
transplant
previou
ebv
lymphoma
follow
treatment
reject
possibl
annual
review
surrog
marker
immunosuppress
small
percentag
patient
develop
high
level
asymptomat
increas
time
posttranspl
absenc
convinc
evid
practic
monitor
group
stabl
patient
viraemia
monitor
follow
common
sens
practic
reduc
immunosuppress
presenc
persist
highlevel
ebv
viraemia
neglig
evid
support
isr
absenc
lymphoma
risk
late
reject
undertaken
cautious
convinc
evid
favour
antivir
prophylaxi
manag
posttranspl
lymphoprolif
disord
requir
specialist
multidisciplinari
approach
discuss
preval
infect
high
popul
infect
earli
childhood
reactiv
common
earli
posttranspl
period
often
coinfect
cmv
clinic
manifest
asymptomat
viraemia
selflimit
viral
ill
dissemin
diseas
pneumon
enceph
lymphadenopathi
bone
marrow
suppress
unit
screen
vast
major
patient
either
asymptomat
settl
spontan
treatment
usual
requir
case
report
death
secondari
worth
consid
diagnosi
patient
unexplain
viral
ill
treatment
requir
gancyclovir
valgancyclovir
exclus
coexist
cmv
reduct
isr
reactiv
childhoodacquir
viru
may
occur
earli
posttranspl
either
asymptomat
nonspecif
viral
ill
sever
diseas
extrem
rare
manag
involv
exclus
like
infect
immunosuppress
reduct
necessari
treatment
foscarnet
cidofovir
main
clinic
manifest
primari
infect
reactiv
reinfect
solidorgan
transplant
develop
kaposi
sarcoma
although
infect
occur
sporad
signific
geograph
bia
seropreval
mediterranean
eastern
europ
middl
east
subsaharan
africa
high
rate
role
immunosuppress
profound
preval
ks
sot
time
gener
popul
occur
transplant
recipi
northwest
europ
transplant
recipi
saudi
arabia
known
risk
factor
posttranspl
ks
shown
tabl
clinic
present
predominantli
cutan
involv
redpurpleblack
nodul
see
fig
typic
lower
bodi
initi
often
associ
lower
limb
oedema
may
preced
develop
skin
lesion
viscer
involv
may
also
occur
includ
lymphadenopathi
pulmonari
nodul
chylou
pleural
effus
gastrointestin
involv
clinic
present
usual
within
first
year
unusu
diagnosi
viscer
ks
delay
particularli
set
gi
involv
mortal
associ
ks
particularli
viscer
involv
around
graft
loss
common
consequ
isr
serolog
rare
help
diagnosi
donor
current
screen
howev
might
worth
consid
donor
recipi
screen
highpreval
area
identifi
risk
histolog
gold
standard
diagnosi
suspici
lesion
biopsi
high
index
suspicion
import
particularli
gastrointestin
involv
pcr
may
consid
tool
monitor
respons
treatment
viscer
ks
although
help
absenc
viraemia
treatment
reduct
immunosuppress
complet
cessat
lifethreaten
viscer
involv
progress
diseas
reduct
immunosuppress
requir
induc
remiss
often
result
graft
loss
convers
cni
mtor
inhibitor
possess
antivegf
activ
signific
success
although
univers
aggress
unrespons
diseas
antivir
foscarnet
cidofovir
chemotherapi
bleomycin
adriamycin
taxol
tri
variabl
success
practic
stop
antiprolif
agent
initi
respons
within
week
signific
viscer
involv
convert
nonproteinur
patient
cni
mtor
inhibitor
intoler
mtor
inhibitor
proceed
stepwis
reduct
cni
ideal
slow
small
cut
rather
larg
cut
diseas
permit
ks
high
risk
recurr
second
transplant
aim
avoid
heavi
induct
plan
earli
switch
mtor
inhibitor
possibl
bk
jc
usual
pick
childhood
remain
latent
presenc
normal
immun
system
caus
signific
nephropathi
polyoma
virusassoci
nephropathi
pvan
renal
transplant
although
rare
transplant
jc
viru
caus
agent
multifoc
leucoencephalopathi
doublestrand
dna
viru
acquir
mostli
childhood
seropreval
excess
remain
latent
renal
tract
immunocompet
individu
intermitt
shed
viru
evid
patholog
consequ
bk
infect
gener
popul
rtr
infect
result
nephropathi
recipi
high
risk
graft
loss
well
caus
ureter
strictur
haemorrhag
cystiti
usual
bmt
incid
pvan
seem
genuin
increas
last
year
registri
data
us
organ
procur
transplant
network
suggest
current
rate
pvan
year
vast
major
occur
first
year
main
risk
factor
appear
relat
total
burden
immunosuppress
use
deplet
antibodi
treatment
acut
reject
combin
tacrolimu
mycophenol
acid
howev
extrem
rare
get
pvan
sot
much
higher
level
part
renal
tract
site
latenc
bkv
addit
known
risk
factor
episod
acut
reject
deceas
donor
ureter
stent
viral
coinfect
may
contribut
infect
tubular
cell
injurydivis
necessari
bkv
growth
also
possibl
serotyp
virul
may
caus
reinfect
clinic
import
natur
histori
pvan
rtr
viruria
preced
get
viraemia
week
diagnosi
pvan
week
thu
offer
window
detect
prevent
usual
clinic
featur
associ
bkv
infect
rtr
except
deterior
renal
function
ureter
obstruct
screen
biopsi
critic
urin
pcr
bkv
dna
sensit
given
high
rate
viruria
lack
specif
pvan
plasma
bkv
dna
sensit
specif
marker
pvan
high
neg
predict
valu
consequ
kdigo
guidelin
recommend
screen
plasma
bkv
dna
monthli
month
follow
monthli
month
altern
plasma
dna
use
urin
cytolog
papanicola
stain
identifi
viral
cytopath
effect
decoy
cell
detach
tubular
epitheli
cell
viral
nuclear
inclus
lower
posit
predict
valu
viraemia
similar
dna
screen
urin
cheaper
nucleic
acid
test
urin
posit
viral
cytopath
effect
prompt
plasma
bkv
dna
screen
plasma
bkv
dna
screen
also
done
context
unexplain
rise
creatinin
ureter
obstruct
everyon
viraemia
develop
pvan
gold
standard
diagnosi
histolog
evid
polyoma
viru
viral
cytopath
chang
nuclear
inclus
interstiti
infiltr
tubul
granuloma
may
also
present
fig
confirm
posit
simian
viru
larg
tantigen
stain
howev
infect
patchi
diseas
may
miss
earli
especi
biopsi
small
superfici
addit
initi
view
biopsi
may
appear
ident
tubul
acut
cellular
reject
biopsi
cellular
infiltr
stain
urgenc
avoid
increas
reduct
necessari
import
note
substanti
data
support
treatment
pvan
apart
isr
although
subject
rct
preemptiv
isr
associ
viral
clearanc
reduct
deathcensor
graft
surviv
varieti
protocol
suggest
isr
face
viraemia
essenti
start
halv
either
mycophenol
acid
azathioprin
reduct
viraemia
either
reduct
cni
stop
antiprolif
altogeth
rapid
abrupt
cut
like
associ
reject
differenti
main
patholog
process
even
stain
difficult
varieti
drug
tri
basi
theoret
vitro
antipolyoma
activ
report
mostli
small
case
seri
nonrandomis
trial
includ
leflunomid
usual
dose
mgday
cidofovir
mgkg
probenecid
everi
week
fluoroquinolon
ivig
mtor
inhibitor
use
leflunomid
comfort
zone
nephrologist
drug
monitor
avail
unit
judg
appropri
dose
therefor
tricki
cidofovir
consider
nephrotox
prehydr
iv
fluid
necessari
subsequ
deterior
renal
function
caus
diagnost
difficulti
littl
evid
fluoroquinolon
reduc
viraemia
evid
current
improv
clinic
outcom
given
high
preval
bkv
infect
ivig
would
seem
harmless
therapeut
option
scarc
resourc
without
evid
base
clear
signific
humor
immun
clear
intracellular
viru
data
convers
mtor
inhibitor
treatment
also
poor
quit
lot
circumstanti
evid
mtor
inhibit
may
reduc
risk
pvan
roughli
half
regimen
possibl
inhibit
cell
cycl
progress
disabl
bkvspecif
tcell
respons
degre
short
sever
lack
decent
evid
support
treatment
pvan
appropri
isr
fail
practic
other
pvan
persist
follow
isr
reject
episod
introduc
mtori
proteinuria
gl
ultim
aim
mtori
monotherapi
origin
report
recount
grim
outcom
term
graft
surviv
roughli
graft
pvan
lost
howev
greater
awar
better
screen
seem
improv
outcom
histolog
grade
system
pvan
devis
base
amount
cellular
involv
extent
interstiti
fibrosi
atrophi
review
takehom
messag
grade
associ
graft
loss
grade
c
graft
loss
ie
earli
detect
isr
like
dramat
help
appli
toxic
medic
advanc
diseas
limit
data
suggest
recurr
rate
loss
second
graft
seem
rare
seem
evid
remov
fail
graft
persist
viraemia
like
risk
factor
remov
immun
respons
suppress
viraemia
would
seem
prudent
jc
viral
infect
commonli
acquir
asymptomat
earli
life
reach
seropreval
middl
age
viruria
detect
normal
individu
viraemia
detect
transplant
patient
despit
clinic
appar
reactiv
form
progress
multifoc
leucoencephalopathi
pml
rare
transplant
caveat
risk
pml
clearli
relat
burden
immunosuppress
case
report
patient
sle
follow
rituximab
transplant
follow
belatacept
well
lessspecif
deplet
antibodi
pml
wide
differenti
may
confus
cni
toxic
treatment
stage
immunosuppress
reduct
mind
immun
reconstitut
syndrom
iri
rapid
withdraw
result
vigor
immun
respons
worsen
clinic
featur
consequ
cidofovir
use
limit
success
issu
retransplant
moot
point
often
pml
whatev
caus
absolut
contraind
might
consid
good
evid
immun
recoveri
absenc
deplet
antibodi
follow
counsel
parvoviru
singlestrand
dna
viru
acquir
respiratori
transmiss
although
transmit
via
transfus
donor
organ
acut
infect
fever
arthriti
rash
sometim
acut
aplast
crisi
mark
anaemia
thrombocytopenia
leucopenia
also
common
nephrot
syndrom
secondari
collaps
focal
segment
glomerulopathi
also
report
diagnosi
made
serolog
igm
pcr
viral
dna
sensit
permit
monitor
respons
viraemia
persist
treatment
aplast
anaemia
glomerulonephr
ivig
gkg
day
import
caus
morbid
posttranspl
term
viral
cutan
anogenit
wart
well
skin
vulval
perian
malign
fig
skin
manifest
manag
viral
wart
discuss
chapter
renal
skin
diseas
worth
rememb
hpv
detect
major
posttranspl
squamou
cell
basal
cell
carcinoma
posttranspl
patient
much
higher
incid
hpv
infect
prooncogen
serotyp
registri
data
show
substanti
excess
cervic
anal
precanc
approxim
increas
vulval
premalign
alarmingli
averag
age
vulval
premalign
group
almost
year
earlier
gener
popul
hpv
vaccin
school
girl
may
help
reduc
incid
women
yet
data
support
routin
vaccin
patient
wait
list
mani
countri
guidelin
recommend
annual
cervic
screen
posttranspl
uk
evid
uptak
extrem
poor
around
someth
could
improv
hepat
e
rna
viru
transmit
faecal
oral
rout
particularli
undercook
meat
predominantli
genotyp
western
countri
associ
high
mortal
acut
hepat
failur
patient
preexist
chronic
liver
diseas
pregnanc
recent
data
suggest
howev
may
associ
chronic
subclin
hepat
solidorgan
transplant
franc
seropreval
pretranspl
reactiv
demonstr
de
novo
case
posttranspl
asymptomat
rest
hepat
approxim
patient
clear
viru
spontan
go
chronic
infect
abnorm
lft
occasion
rapid
progress
cirrhosi
howev
overal
preval
chronic
infect
known
make
diagnosi
import
clearanc
viru
may
prevent
cirrhosi
suspect
diagnosi
made
rna
blood
stool
treatment
isr
fail
success
report
pegal
interferon
ribavirin
cellmedi
immun
appear
particularli
import
defenc
legionella
pneumophila
consequ
sot
recipi
substanti
risk
expos
usual
contamin
aircondit
system
water
tank
outbreak
high
fever
cough
flulik
symptom
norm
cxr
may
show
focal
nodular
lobar
diffus
consolid
sometim
cavit
urin
legionella
antigen
test
quick
detect
serogroup
pneumophila
micdadei
unlik
pair
legionella
serolog
rare
help
real
time
mycoplasma
chlamydia
pcr
legionella
done
bal
sampl
treatment
macrolid
ideal
azithromycin
caus
less
inhibit
cytochrom
fluroquinolon
rifampicin
mark
induc
cytochrom
dual
therapi
sick
patient
sinc
test
may
diagnost
atyp
pathogen
cover
consid
ideal
macrolid
sot
recipi
lower
respiratori
tract
infect
listeria
monocytogen
environment
gramposit
bacillu
contract
oral
pet
domest
anim
unpasteuris
poorli
kept
food
consequ
occur
outbreak
well
sporad
listeria
infect
associ
high
mortal
especi
immunocompromis
intracellular
normal
erad
cellmedi
immun
disabl
sot
common
caus
bacteri
mening
sot
addit
tropism
brain
parenchyma
incub
within
h
ingest
symptom
develop
within
week
clinic
present
nonspecif
fever
possibl
follow
diarrhoeal
ill
malais
mening
enceph
abscess
fig
diagnosi
typic
made
blood
cultur
examin
csf
treatment
intraven
ampicillin
g
everi
h
gentamycin
mgkg
three
divid
dose
usual
ad
immunocompromis
patient
trimethoprimsulphamethoxazol
septrin
altern
penicillinallerg
patient
nocardia
rare
seriou
opportunist
infect
posttranspl
caus
actinomycet
nocardia
speci
mostli
acquir
inhal
occasion
via
skin
inocul
incid
report
literatur
around
probabl
repres
report
bia
evid
less
common
part
univers
prophylaxi
septrin
review
english
literatur
case
report
follow
renal
transplant
show
huge
variat
onset
week
year
vast
major
case
present
primari
pulmonari
involv
signific
proport
go
dissemin
diseas
predilect
brain
cutan
involv
fig
pulmonari
involv
typic
present
classic
pneumonia
fever
lung
nodul
caviti
common
cerebr
involv
may
insidi
nonspecif
headach
confus
focal
neurolog
sign
also
associ
fever
norcardia
especi
dissemin
diseas
associ
signific
mortal
earli
diagnosi
biopsi
unexplain
skin
nodul
access
lesion
essenti
treatment
earli
pulmonari
diseas
sulphonamid
usual
trimethoprimsulphamethoxazol
mgkgday
sever
pulmonari
cerebr
involv
imipenem
amikacin
ad
caveat
nocardia
speci
resist
biopsi
cultur
sensit
import
treatment
must
prolong
month
pulmonari
cerebr
involv
incid
activ
tb
renal
transplant
western
countri
higher
gener
popul
asia
rate
report
apart
countri
origin
diabet
chronic
liver
diseas
burden
immunosuppress
eg
use
deplet
antibodi
signific
risk
factor
screen
pretranspl
difficult
tuberculin
skin
test
eg
mantoux
test
help
posit
often
result
fals
neg
patient
esrd
patient
previou
bcg
may
fals
posit
cxr
sign
previou
tb
clearli
help
interferon
gamma
releas
assay
may
help
distinguish
previou
exposur
activ
diseas
neg
patient
esrd
posttranspl
clinic
present
occur
averag
month
posttranspl
major
infect
thought
reactiv
roughli
due
primari
infect
small
percentag
donor
deriv
fever
appear
promin
featur
occur
weight
loss
asthenia
strikingli
twothird
patient
present
extrapulmonari
diseas
compar
gener
popul
fig
consequ
tissu
biopsi
ensur
procedurist
send
sampl
cultur
import
make
diagnosi
immunocompromis
patient
mycobacteri
burden
often
high
mycobacteri
blood
cultur
may
help
especi
set
dissemin
atyp
mycobacteri
infect
eg
mycobacterium
aviumintracellular
complex
infect
see
manag
mtb
sot
standard
antitb
treatment
present
issu
term
drug
interact
main
one
induct
cytochrom
rifampicin
result
mark
reduct
cni
level
usual
tripl
dose
cni
within
first
week
rifampicinbas
therapi
importantli
convers
true
rifampicin
stop
need
signific
dose
reduct
critic
therefor
close
liaison
infecti
diseas
team
nephrologist
treatment
often
accompani
isr
need
done
caution
tb
neurolog
site
iri
may
result
deterior
result
recent
retrospect
analysi
franc
suggest
good
outcom
mortal
much
improv
histor
data
littl
impact
graft
surviv
except
develop
haemophagocyt
syndrom
augur
poorli
ntm
ubiquit
environment
pathogen
becom
opportunist
infect
sot
donorderiv
ntm
document
rare
overal
incid
ntm
clear
case
report
infect
renal
transplant
mani
ntm
speci
common
appear
mycobacterium
avium
complex
mac
kansasii
xenopi
averag
present
year
posttranspl
sot
exclud
lung
transplant
major
diseas
extrapulmonari
cxr
normal
present
usual
cutan
erythemat
nodul
tenosynov
arthriti
also
common
often
one
site
constitut
symptom
often
absent
mac
common
recipi
chronic
lung
diseas
colonis
facilit
therefor
make
diagnosi
ntb
infect
set
difficult
american
thorac
societi
issu
guidelin
involv
combin
consist
clinic
radiolog
find
exclus
diseas
cultur
bal
biopsi
specimen
debrid
may
necessari
cutan
involv
firstlin
agent
often
involv
azithromycin
ethambutol
rifabutin
treatment
specialist
area
requir
liaison
infecti
diseas
team
varieti
fungal
infect
occur
rtr
burden
immunosuppress
esp
use
deplet
antibodi
multipl
reject
episod
highdos
steroid
compromis
innat
immun
system
cmv
viraemia
diabet
mellitu
signific
risk
factor
consequ
major
seriou
fungal
infect
occur
within
first
month
cryptococc
infect
import
except
compar
sot
rtr
rel
spare
fungal
infect
rate
report
rate
pancrea
recipi
much
higher
review
nearli
rtr
invas
fungal
infect
candida
cryptococcu
aspergillu
three
common
fungal
infect
may
trivial
colonis
fungi
discuss
caus
invas
diseas
high
mortal
earli
diagnosi
critic
azol
use
treat
sever
fungal
infect
profound
inhibitori
effect
cytochrom
consequ
absenc
close
monitor
start
azol
highli
like
render
fungaem
patient
cni
toxic
candida
infect
common
fungal
infect
rtr
usual
present
orogenit
involv
see
fig
especi
set
steroid
exposur
diabet
mellitu
also
account
invas
fungal
infect
beyond
mucocutan
infect
candida
involv
gut
sever
oesophag
particularli
common
urinari
tract
lung
focal
caviti
pneumon
central
nervou
system
heart
valv
prophylaxi
nystatin
ml
qd
pretti
effect
prevent
oral
candidiasi
long
patient
take
discontinu
prophylaxi
steroid
stop
mg
clotrimazol
oral
fluconazol
mg
od
distinguish
colonis
uti
respiratori
tract
infect
difficult
judgement
call
must
made
biopsyproven
tissu
involv
posit
blood
cultur
need
rapid
treatment
candida
albican
sensit
azol
c
glabrata
c
krusei
often
resist
treatment
oesophag
system
involv
fluconazol
caspofungin
voriconazol
posaconazol
amphotericin
aspergillu
niger
common
harmless
tongu
infect
wherea
fumigatu
flavu
respons
invas
fungal
infect
rtr
fungal
infect
risk
factor
total
burden
immunosuppress
diabet
mellitu
chronic
liver
diseas
cmv
viraemia
exposur
build
work
smoke
marijuana
also
implic
common
present
pneumonia
rhinocerebr
see
fig
sinu
gut
skin
involv
also
occur
dyspnoea
unproduct
cough
fever
usual
haemoptysi
may
torrenti
occur
classic
appear
ct
scan
pulmonari
nodul
halo
sign
suggest
angioinvas
aspergillosi
patient
may
often
present
infiltr
consolid
high
index
suspicion
invas
aspergillosi
eg
nonrespons
broadspectrum
antibiot
bronchoalveolar
lavag
transbronchi
biopsi
may
requir
serum
galactomannan
though
use
may
low
sensit
specif
sot
recipi
bal
galactomannan
may
better
specif
set
cultur
cytologyhistopatholog
find
specif
treatment
invas
diseas
iv
voriconazol
effect
liposom
amphotericin
altern
caspofungin
combin
immunosuppress
reduct
context
aspergilloma
invas
preexist
cavitari
lung
diseas
pulmonari
arteri
embolis
surgic
resect
may
requir
surgic
debrid
may
also
requir
patient
invas
aspergillosi
impend
massiv
haemorrhag
case
rhinosinus
mortal
high
emphasi
earli
diagnosi
aggress
treatment
durat
therapi
depend
clinic
respons
cn
opportunist
environment
pathogen
highest
risk
exposur
relat
bird
bird
guano
histor
data
suggest
infect
rate
rtr
appear
higher
sot
account
invas
fungal
infect
although
may
reflect
previous
higher
use
steroid
clinic
experi
suggest
much
lower
rate
rtr
current
patient
may
show
sign
neurolog
pulmonari
cutan
involv
pneumonia
characterist
featur
dyspnoea
cough
common
xray
may
show
either
nodul
lobar
consolid
cutan
involv
occur
use
diagnost
focu
meningoenceph
often
indol
nonspecif
present
result
delay
diagnosi
headach
week
irrit
confus
absenc
classic
sign
mening
ultim
progress
reduct
conscious
focal
cranial
nerv
palsi
import
diagnosi
miss
high
index
suspicion
requir
lumber
punctur
high
open
pressur
moder
elev
csf
protein
low
white
cell
count
predominantli
lymphocyt
low
csf
serum
glucos
ratio
characterist
specif
find
indianink
stain
cryptococc
antigen
test
must
alway
request
set
treatment
cryptococcu
infect
rtr
associ
high
rate
iri
present
roughli
week
reduct
immunosuppress
clinician
must
awar
risk
associ
hydrocephalu
low
threshold
reimag
initi
treatment
liposom
amphotericin
flucytosin
first
week
follow
highdos
fluconazol
mgday
week
follow
secondari
prophylaxi
fluconazol
mgday
least
month
lifelong
peripher
blood
cell
remain
morbid
mortal
cryptococc
mening
mainli
associ
rais
intracrani
pressur
result
csf
absorpt
blockad
repeat
lumber
punctur
remov
csf
requir
first
week
therapi
mucormycosi
rare
opportunist
fungal
infect
commonli
document
debilit
poorli
control
diabet
also
document
renal
transplant
invas
fungal
infect
risk
factor
includ
prolong
neutropenia
diabet
ironchel
therapi
well
immunosuppress
mucocutan
particularli
orofaci
rhinocerebr
pulmonari
involv
common
propens
invad
vessel
fatal
outcom
pulmonari
haemorrhag
dissemin
common
fig
treatment
iv
liposom
amphotericin
posaconazol
altern
dual
therapi
surgic
resect
pulmonari
extrapulmonari
tissu
import
mortal
mucormycosi
rtr
remain
highest
fungal
infect
endem
fungi
respons
invas
fungal
infect
sot
high
mortal
fungi
occur
sw
usa
central
south
america
histoplasma
also
report
europ
asia
africa
outbreak
condit
describ
rtr
rare
case
donorderiv
infect
also
report
howev
major
infect
appear
reactiv
occur
within
month
primari
infect
occur
stage
main
exposur
risk
histoplasma
bird
bat
guano
histoplasmosi
rtr
may
present
fever
cellul
mouth
ulcer
oronasopharynx
pulmonari
mening
involv
fungal
cultur
may
take
week
fungal
infect
biopsi
help
urin
antigen
screen
high
sensit
wide
avail
histopatholog
examin
may
show
characterist
intracellular
organ
immunocompet
individu
coccidioidomycosi
almost
exclus
caus
pulmonari
involv
sot
extrapulmonari
commonli
involv
liver
bone
marrow
mening
guidelin
recommend
serolog
screen
author
advoc
donor
recipi
endem
region
firstlin
treatment
fungi
liposom
amphotericin
itraconazol
second
line
histoplasmosi
fluconazol
caspofungin
coccidioidomycosi
accompani
isr
fatal
relaps
occur
usual
treat
azol
least
year
mening
involv
usual
life
cryptosporidium
parvum
associ
drink
water
swim
pool
livestock
caus
chronic
disabl
diarrhoea
rtr
waterymucoid
associ
abdomin
pain
individu
selflimit
ill
patient
normal
screen
one
studi
sot
diarrhoea
case
attribut
cryptosporidium
probabl
underdiagnos
practic
cryptosporidium
ag
test
elisa
highli
sensit
good
specif
worth
consid
rtr
cultureneg
diarrhoea
respons
replac
usual
suspect
medic
specif
treatment
spiramycin
nitazoxanid
paromomycin
tri
success
relaps
occur
toxoplasma
gondii
opportunist
parasit
caus
diseas
rtr
reactiv
primari
infect
occasion
donor
transmiss
risk
factor
includ
seroneg
statu
recipi
seroposit
donor
burden
immunosuppress
count
lack
septrin
prophylaxi
exposur
cat
reactiv
donorderiv
infect
tend
present
within
first
month
transplant
pneumon
twothird
neurolog
involv
twothird
postmortem
cardiac
involv
also
common
fever
common
neurolog
symptom
nonspecif
headach
confus
ultim
coma
serolog
realli
help
diagnos
risk
seroconvers
often
slow
rare
help
make
diagnosi
diagnosi
may
made
contrast
ct
mri
scan
show
multipl
ringenhanc
lesion
appropri
radiolog
respons
week
treatment
cn
ringenhanc
lesion
sot
recipi
may
due
number
caus
appropri
respons
treatment
seen
stereotact
brain
biopsi
may
requir
safe
csf
examin
csf
toxoplasma
dna
detect
pcr
highli
sensit
specif
cn
toxoplasmosi
septrin
prophylaxi
pcp
effect
prevent
toxoplasmosi
reactiv
occur
stop
treatment
pyrimethamin
mg
load
dose
follow
mg
daili
folin
acid
plu
sulphadiazin
week
septrin
mgkg
day
mortal
remain
high
primari
infect
particularli
risk
strongyloidiasi
set
sot
rare
seriou
condit
mortal
around
strongyloid
endem
larg
area
tropic
subtrop
initi
infect
via
larval
penetr
skin
usual
asymptomat
larva
migrat
pulmonari
vessel
via
swallow
sputum
duodenum
jejunum
matur
femal
larva
shed
egg
importantli
infect
remain
quiescent
year
histori
live
endem
area
import
transplant
endem
area
reactiv
hyperinfest
occur
previou
exposur
significantli
immunocompromis
usual
within
month
sometim
within
first
month
occasion
year
transplant
present
tend
predominantli
respiratori
gastrointestin
abdomin
pain
diarrhoea
nausea
vomit
abdomin
distens
may
lead
ileu
respiratori
involv
tachypnoea
dyspnoea
fever
cough
ard
occur
twothird
case
cxr
usual
abnorm
diffus
patchi
infiltr
eosinophilia
although
help
clue
often
present
although
may
well
present
miss
pretranspl
blood
diagnosi
may
made
visualis
larva
sputum
stool
high
falseneg
rate
multipl
stool
sampl
may
necessari
duoden
aspir
bronchoalveolar
lavag
enterotest
piec
string
tape
nose
pass
duodenum
withdrawn
microscopi
support
worth
consid
clinic
suspicion
treatment
ivermectin
mcgkg
often
day
hyperinfest
day
other
along
broadspectrum
antibiot
repeat
treatment
evid
gut
transloc
patient
deterior
rapidli
hyperinfest
either
via
ard
recurr
gramneg
septicaemia
larva
burrow
gut
earli
identif
therefor
critic
sensibl
approach
check
strongyloid
serolog
patient
endem
area
prelist
posit
unexplain
eosinophilia
stool
screen
ova
cyst
parasit
id
opinion
sought
regard
blind
erad
chaga
diseas
trypanosoma
cruzi
endem
central
south
america
caus
diseas
rtr
reactiv
seroposit
patient
donorderiv
infect
seroposit
donor
infect
result
fever
myocard
meningoenceph
cutan
involv
pannicul
typic
within
year
transplant
pretranspl
serolog
treatment
current
recommend
part
toxic
treatment
close
surveil
posttranspl
r
diagnosi
manag
treatment
trypanosomiasi
undertaken
infecti
diseas
team
benzinidazol
treatment
choic
nifurtimox
altern
week
context
parasitaemia
result
hyperinfest
sever
secondari
bacteri
infect
fig
pruriti
may
subdu
sourc
cellul
immedi
appar
consider
merit
robust
system
properli
screen
patient
wait
list
live
donor
appropri
vaccin
treatment
plan
prophylaxisethn
travel
countri
origin
histori
recipi
possibl
donor
obtain
especi
investig
fever
posttransplantcultur
perfus
fluid
retent
donor
serum
serolog
screen
necessari
cheap
strategi
may
help
identifi
donor
infectionsrobust
strategi
need
place
ensur
appropri
chemoprophylaxi
dose
durat
extens
receiv
deplet
antibodi
low
ig
count
receiv
treatment
late
rejectiona
close
relationship
virolog
microbiolog
depart
vital
rapid
alert
system
email
alert
viraemia
posit
msu
invaluablemani
opportunist
infect
atyp
present
absenc
diagnosi
improv
empir
therapi
biopsi
histolog
cultur
may
critic
